comparemela.com

Abbvie Canada News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Health Canada Approves AbbVie s RINVOQ® (upadacitinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Approval is based on results from three Phase 3 studies: two for induction and one for maintenance 1,2,3In clinical trials, patients taking RINVOQ achieved the primary endpoint of clinical remission .

vimarsana © 2020. All Rights Reserved.